Advertisement

CardioVascular and Interventional Radiology

, Volume 40, Issue 2, pp 177–191 | Cite as

CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma

  • Miltiadis E. Krokidis
  • Franco Orsi
  • Konstantinos Katsanos
  • Thomas Helmberger
  • Andy Adam
CIRSE Standards of Practice Guidelines

Introduction

Overview of Renal Cell Carcinoma

Renal cell carcinoma (RCC) comprises approximately 3.8% of all new cancers in the western world; the detection rate of RCC has been increasing in the past 10 years by approximately 1.7% per year [1]. This rise is attributed to the increased number of diagnostic cross-sectional scans in which asymptomatic renal tumours are incidentally detected. The median age at diagnosis is 64 years [2].

RCC may be sporadic or congenital. Sporadic RCC has an established link with smoking and obesity. Congenital RCC is linked to specific gene mutations. The autosomal dominant mutation of the von Hippel–Lindau (VHL) gene predisposes to clear cell RCC [3, 4]. Another predisposing mutation is that of the germline MET proto-oncogene (MET). Germline mutations of MET have been detected primarily in patients with hereditary papillary RCC, whereas somatic MET mutations are also detected in 5–13% of patients with sporadic papillary RCC [5, 6].

The most widely...

Keywords

Renal cell carcinoma Minimal invasive treatment Ablation CIRSE Guidelines 

Notes

Acknowledgements

The authors would like to thank Dr Maria Pantelidou for data collection and Dr Chris Cummins for the language editing of the manuscript.

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM. Hereditary renal cancers. Radiology. 2003;226:33–46.PubMedCrossRefGoogle Scholar
  4. 4.
    DeVita Jr VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.Google Scholar
  5. 5.
    Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biological complexity. Eur Urol. 2015;67:85–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Bex A. Classification of renal cell carcinoma subtypes: there is more than meets the eye. Eur Urol. 2015;67:98–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–63.PubMedCrossRefGoogle Scholar
  8. 8.
    Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyon: IARC Press; 2004. p. 7.Google Scholar
  9. 9.
    Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37:1469–89.PubMedCrossRefGoogle Scholar
  10. 10.
    Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. Radiographics. 2008;28(5):1325–38.PubMedCrossRefGoogle Scholar
  11. 11.
    Zagoria RJ, Dyer RB, Wolfman NT, Hinn GC, Chen YM. Radiology in the diagnosis and staging of renal cell carcinoma. Crit Rev Diagn Imaging. 1990;31(1):81–115.PubMedGoogle Scholar
  12. 12.
    Choudhary S, Rajesh A, Mayer NJ, Mulcahy KA, Haroon A. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. Clin Radiol. 2009;64(5):517–22.PubMedCrossRefGoogle Scholar
  13. 13.
    Millet I, Doyon FC, Hoa D, Thuret R, Merigeaud S, Serre I, et al. Characterization of small solid renal lesions: can benign and malignant tumors be differentiated with CT? AJR. 2011;197:887–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Rosenkrantz AB, Hindman N, Fitzgerald EF, Niver BE, Melamed J, Babb JS. MRI features of renal oncocytoma and chromophobe renal cell carcinoma. AJR Am J Roentgenol. 2010;195(6):W421–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Hindman N, Ngo L, Genega EM, Melamed J, Wei J, Braza JM, et al. Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? Radiology. 2012;265(2):468–77.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Pedrosa I, Sun MR, Spencer M, Genega EM, Olumi AF, Dewolf WC, et al. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics. 2008;28(4):985–1003.PubMedCrossRefGoogle Scholar
  17. 17.
    Putra LG, Minor TX, Bolton DM, Appu S, Dowling CR, Neerhut GJ. Improved assessment of renal lesions in pregnancy with magnetic resonance imaging. Urology. 2009;74(3):535–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Lanzman RS, Robson PM, Sun MR, Patel AD, Mentore K, Wagner AA, et al. Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings. Radiology. 2012;265(3):799–808.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Capitanio U, Montorsi F. Renal cancer. Lancet. 2015. (epub ahead of print).Google Scholar
  20. 20.
  21. 21.
    Maxwell NJ, Saleem AN, Rogers E, Kiely D, Sweeney P, Brady AP. Renal artery embolisation in the palliative treatment of renal carcinoma. Br J Radiol. 2007;80(950):96–102.PubMedCrossRefGoogle Scholar
  22. 22.
    Guy L, Alfidja AT, Chabrot P, Ravel A, Boiteux JP, Boyer L. Palliative transarterial embolization of renal tumors in 20 patients. Int Urol Nephrol. 2007;39(1):47–50.PubMedCrossRefGoogle Scholar
  23. 23.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRefGoogle Scholar
  24. 24.
    McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59:816–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy vs. radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181(1):55–61.PubMedCrossRefGoogle Scholar
  26. 26.
    Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer. 2009;115(7):1465–71.PubMedCrossRefGoogle Scholar
  27. 27.
    Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008;179(2):468–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Patard JJ, Bensalah KC, Pantuck AJ, Klatte T, Crepel M, Verhoest G, et al. Radical nephrectomy is not superior to nephron sparing surgery in PT1B-PT2N0M0 renal tumours: A matched comparison analysis in 546 cases. Eur Urol Suppl. 2008;7(3):194.CrossRefGoogle Scholar
  29. 29.
    Kutikov A, Uzzo RG. The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009;56(5):786–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurement using the C index method. J Urol. 2010;183(5):1708–13.PubMedCrossRefGoogle Scholar
  32. 32.
    Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Rais-Bahrami S, Guzzo TJ, Jarrett TW, Kavoussi LR, Allaf ME. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int. 2009;103:1355–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995;197:589–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Oda T, Miyao N, Takahashi A, Yanase M, Masumori N, Itoh N, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001;8:473–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Guðmundsson E, Hellborg H, Lundstam S, Erikson S, Ljungberg B, Swedish Kidney Cancer Quality Register Group. Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data. Eur Urol. 2011;60(5):975–82.PubMedCrossRefGoogle Scholar
  37. 37.
    McGovern FJ, Wood BJ, Goldberg SN, Mueller PR. Radiofrequency ablation of renal cell carcinoma via image guided needle electrodes. J Urol. 1999;161(2):599–600.PubMedCrossRefGoogle Scholar
  38. 38.
    Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma. Part 1. Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR. 2005;185:64–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Zagoria RJ, Hawkins AD, Clark PE, Hall MC, Matlaga BR, Dyer RB, et al. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. AJR. 2004;183:201–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Georgiades CS, Rodriguez R. Efficacy and safety of percutaneous cryoablation for stage 1A/B renal cell carcinoma: results of a prospective, single-arm, 5-year study. Cardiovasc Interv Radiol. 2014;37(6):1494–9.CrossRefGoogle Scholar
  41. 41.
    Breen D, Bryant TJ, Abbas A, Shepherd B, McGill N, Anderson JA, et al. Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int. 2013;112(6):758–65.PubMedCrossRefGoogle Scholar
  42. 42.
    Schmit GD, Schenck LA, Thompson RH, Boorjian SA, Kurup AN, Weisbrod AJ, et al. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology. 2014;272(3):903–10.PubMedCrossRefGoogle Scholar
  43. 43.
    Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24.PubMedCrossRefGoogle Scholar
  44. 44.
    Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):49–56.CrossRefGoogle Scholar
  45. 45.
    Georgiades C, Rodriguez R. Renal tumor ablation. Tech Vasc Interv Radiol. 2013;16(4):230–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Schmit GD, Kurup AN, Weisbrod AJ, Thompson RH, Boorjian SA, Wass CT, et al. ABLATE: a renal ablation planning algorithm. AJR Am J Roentgenol. 2014;202(4):894–903.PubMedCrossRefGoogle Scholar
  47. 47.
    Warshauer DM, McCarthy SM, Street L, Bookbinder MJ, Glickman MG, Richter J, et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology. 1988;169(2):363–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Paudice N, Zanazzi M, Agostini S, Bertelli E, Caroti L, Carta P, et al. Contrast-enhanced ultrasound assessment of complex cystic lesions in renal transplant recipients with acquired cystic kidney disease: preliminary experience. Transplant Proc. 2012;44(7):1928–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Sahni VA, Silverman G. Imaging management of incidentally detected small renal masses. Semin Interv Radiol. 2014;31:9–19.CrossRefGoogle Scholar
  50. 50.
    Grobner T. Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4):1104–8.PubMedCrossRefGoogle Scholar
  51. 51.
    http://www.esur.org/guidelines/. Accessed Nov 2015.
  52. 52.
    Tsiviam M, Rampersaud Jr EN, del Pilar Laguna Pes M, Joniau S, Leveillee RJ, Shingleton WB, et al. Small renal mass biopsy–how, what and when: report from an international consensus panel. BJU Int. 2014;113(6):854–63.CrossRefGoogle Scholar
  53. 53.
    Breda A, Treat EG, Haft-Candell L, Leppert JT, Harper JD, Said J, et al. Comparison of accuracy of 14-, 18- and 20-G needles in ex vivo renal mass biopsy: a prospective, blinded study. BJU Int. 2010;105(7):940–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Veltri A, Garetto I, Tosetti I, Busso M, Volpe A, Pacchioni D, et al. Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol. 2011;21(2):393–401.PubMedCrossRefGoogle Scholar
  55. 55.
    Uppot RN, Silverman SG, Zagoria RJ, Tuncali K, Childs DD, Gervais DA. Imaging-guided percutaneous ablation of renal cell carcinoma: a primer of how we do it. AJR Am J Roentgenol. 2009;192(6):1558–70.PubMedCrossRefGoogle Scholar
  56. 56.
    Breen DJ, Railton NJ. Minimally invasive treatment of small renal tumors: trends in renal cancer diagnosis and management. Cardiovasc Interv Radiol. 2010;33(5):896–908.CrossRefGoogle Scholar
  57. 57.
    Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727–36.PubMedCrossRefGoogle Scholar
  58. 58.
    Goldberg SN, Gazelle GS. Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology. 2001;48:359–67.PubMedGoogle Scholar
  59. 59.
    Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology. 2002;60(2 Suppl 1):40–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Veltri A, De Fazio G, Malfitana V, Isolato G, Fontana D, Tizzani A, et al. Percutaneous US-guided RF thermal ablation for malignant renal tumors: preliminary results in 13 patients. Eur Radiol. 2004;14:2303–10.PubMedCrossRefGoogle Scholar
  61. 61.
    Georgiades C, Rodriguez R, Azene E, Weiss C, Chaux A, Gonzalez-Roibon N, et al. Determination of the nonlethal margin inside the visible “ice-ball” during percutaneous cryoablation of renal tissue. Cardiovasc Interv Radiol. 2013;36(3):783–90.CrossRefGoogle Scholar
  62. 62.
    Weld KJ, Hruby G, Humphrey PA, Ames CD, Landman J. Precise characterization of renal parenchymal response to single and multiple cryoablation probes. J Urol. 2006;176(2):784–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Campbell SC, Krishnamurthi V, Chow G, Hale J, Myles J, Novick AC. Renal cryosurgery: experimental evaluations of treatment parameters. Urology. 1998;52(1):29–34.PubMedCrossRefGoogle Scholar
  64. 64.
    Lubner MG, Brace CL, Ziemlewicz TJ, Hinshaw JL, Lee Jr FT. Microwave ablation of hepatic malignancy. Semin Interv Radiol. 2013;30(1):56–66.CrossRefGoogle Scholar
  65. 65.
    Liang P, Wang Y. Microwave ablation of hepatocellular carcinoma. Oncology. 2007;72(Suppl 1):124–31.PubMedCrossRefGoogle Scholar
  66. 66.
    Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee Jr FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236:132–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Knavel EM, Hinshaw JL, Lubner MG, Andreano A, Warner TF, Lee Jr FT, et al. High-powered gas-cooled microwave ablation: shaft cooling creates an effective stick function without altering the ablation zone. AJR Am J Roentgenol. 2012;198:W260–5.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Cheng Z, Xiao Q, Wang Y, Sun Y, Lu T, Liang P. 915 MHz microwave ablation with implanted internal cooled-shaft antenna: initial experimental study in in vivo porcine livers. Eur J Radiol. 2011;79:131–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Horn JC, Patel RS, Kim E, Nowakowski FS, Lookstein RA, Fischman AM. Percutaneous microwave ablation of renal tumors using a gas-cooled 2.4-GHz probe: technique and initial results. J Vasc Interv Radiol. 2014;25(3):448–53.PubMedCrossRefGoogle Scholar
  70. 70.
    Wah TM, Irving HC. Infectious complications after percutaneous radiofrequency ablation of renal cell carcinoma in patients with ileal conduit. J Vasc Interv Radiol. 2008;19(9):1382–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Fotiadis NI, Sabharwal T, Morales JP, Hodgson DJ, O’Brien TS, Adam A. Combined percutaneous radiofrequency ablation and ethanol injection of renal tumours: midterm results. Eur Urol. 2007;52(3):777–84.PubMedCrossRefGoogle Scholar
  72. 72.
    Krokidis M, Spiliopoulos S, Jarzabek M, Fotiadis N, Sabharwal T, O’Brien T, et al. Percutaneous radiofrequency ablation of small renal tumours in patients with a single functioning kidney: long-term results. Eur Radiol. 2013;23(7):1933–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Boss A, Clasen S, Kuczyk M, Anastasiadis A, Schmidt D, Graf H, et al. Magnetic resonance-guided percutaneous radiofrequency ablation of renal cell carcinomas: a pilot clinical study. Invest Radiol. 2005;40:583–90.PubMedCrossRefGoogle Scholar
  74. 74.
    Gupta A, Allaf ME, Kavoussi LR, Jarrett TW, Chan DY, Su LM, et al. Computerized tomography guided percutaneous renal cryoablation with the patient under conscious sedation: initial clinical experience. J Urol. 2006;175:447–52.PubMedCrossRefGoogle Scholar
  75. 75.
    Miki K, Shimomura T, Yamada H, Kishimoto K, Ohishi Y, Harada J, et al. Percutaneous cryoablation of renal cell carcinoma guided by horizontal open magnetic resonance imaging. Int J Urol. 2006;13:880–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Park BK, Kim SH, Byun JY, Kim YS, Kwon GY, Jang IS. CT-guided instillation of 5% dextrose in water into the anterior pararenal space before renal radiofrequency ablation in a porcine model: positive and negative effects. J Vasc Interv Radiol. 2007;18:1561–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Kam AW, Littrup PJ, Walther MM, Hvizda J, Wood BJ. Thermal protection during percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol. 2004;15(7):753–8.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Wah TM, Koenig P, Irving HC, Gervais DA, Mueller PR. Radiofrequency ablation of a central renal tumour: protection of the collecting system with a retrograde cold dextrose pyeloperfusion technique. J Vasc Interv Radiol. 2005;16(11):1551–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Cantwell CP, Wah TM, Gervais DA, Eisner BH, Arellano R, Uppot RN, et al. Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water. J Vasc Interv Radiol. 2008;19(7):1034–40.PubMedCrossRefGoogle Scholar
  80. 80.
    Tacke J, Mahnken A, Bucker A, Rohde D, Gunther RW. Nephron-sparing percutaneous ablation of a 5 cm renal cell carcinoma by superselective embolization and percutaneous RF-ablation. Rofo. 2001;173:980–3.PubMedCrossRefGoogle Scholar
  81. 81.
    Tacke J, Mahnken AH, Gunther RW. Percutaneous thermal ablation of renal neoplasms. Rofo. 2005;177:1631–40.PubMedCrossRefGoogle Scholar
  82. 82.
    Mahnken AH, Penzkofer T, Bruners P, Günther RW, Brehmer B. Interventional management of a renal cell carcinoma by radiofrequency ablation with tagging and cooling. Korean J Radiol. 2009;10(5):523–6.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Meloni MF, Bertolotto M, Alberzoni C, Lazzaroni S, Filice C, Livraghi T, et al. Follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: contrast-enhanced sonography versus contrast-enhanced CT or MRI. AJR Am J Roentgenol. 2008;191(4):1233–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Rutherford EE, Cast JE, Breen DJ. Immediate and long-term CT appearances following radiofrequency ablation of renal tumours. Clin Radiol. 2008;63(2):220–30.PubMedCrossRefGoogle Scholar
  85. 85.
    Smith S, Gillams A. Imaging appearances following thermal ablation. Clin Radiol. 2008;63:1–11.PubMedCrossRefGoogle Scholar
  86. 86.
    Merkle EM, Nour SG, Lewin JS. MR imaging follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: findings in 18 patients during first 6 months. Radiology. 2005;235:1065–71.PubMedCrossRefGoogle Scholar
  87. 87.
    Philllips B, Ball C, Sacket D, Badenoch D, Straus S, Haynes B, et al. Oxford Centre for Evidence-Based Medicine-Levels of Evidence (2009). Centre for Evidence-Based Medicine. www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009. Accessed Nov 2015.
  88. 88.
    Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol. 2013;63(3):486–92.PubMedCrossRefGoogle Scholar
  89. 89.
    Lane BR, Campbell SC, Gill IS. 10-year oncologic outcomes after laparoscopic and open partial nephrectomy. J Urol. 2013;190(1):44–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Katsanos K, Mailli L, Krokidis M, McGrath A, Sabharwal T, Adam A. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Interv Radiol. 2014;37(2):427–37.CrossRefGoogle Scholar
  91. 91.
    Takaki H, Yamakado K, Soga N, Arima K, Nakatsuka A, Kashima M, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol. 2010;28(6):460–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2015;67(2):252–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Ma Y, Bedir S, Cadeddu JA, Gahan JC. Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours. BJU Int. 2014;113:51–5.PubMedCrossRefGoogle Scholar
  94. 94.
    Breen DJ, Rutherford EE, Stedman B, Roy-Choudhury SH, Cast JEI, Hayes MC, et al. Management of renal tumors by image-guided radiofrequency ablation: experience in 105 tumors. Cardiovasc Interv Radiol. 2007;30(5):936–42.CrossRefGoogle Scholar
  95. 95.
    Zagoria RJ, Pettus JA, Rogers M, Werle DM, Childs D, Leyendecker JR. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology. 2011;77(6):1393–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Veltri A, Gazzera C, Busso M, Solitro F, Piccoli GB, Andreetto B, et al. T1a as the sole selection criterion for RFA of renal masses: randomized controlled trials versus surgery should not be postponed. Cardiovasc Interv Radiol. 2014;37(5):1292–8.CrossRefGoogle Scholar
  97. 97.
    Kim SD, Yoon SG, Sung GT. Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients. Korean J Radiol. 2012;13(5):625–33.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Atwell TD, Schmit GD, Boorjian SA, Mandrekar J, Kurup AN, Weisbrod AJ, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol. 2013;200(2):461–6.PubMedCrossRefGoogle Scholar
  99. 99.
    Zargar H, Atwell TD, Cadeddu JA, de la Rosette JJ, Janetschek G, Kaouk JH, et al. Cryoablation for small renal masses: selection criteria, complications, and functional and oncologic results. Eur Urol. 2016;69(1):116–28.PubMedCrossRefGoogle Scholar
  100. 100.
    Zorn KC, Orvieto MA, Mikhail AA, Lyon MB, Gerber GS, Steinberg GD, et al. Case report: radiofrequency ablation-induced renal-pelvic obstruction resulting in nephrectomy. J Endourol. 2007;21(9):1059–63.PubMedCrossRefGoogle Scholar
  101. 101.
    Park BK, Kim CK. Complications of image-guided radiofrequency ablation of renal cell carcinoma: causes, imaging features and prevention methods. Eur Radiol. 2009;19(9):2180–90.PubMedCrossRefGoogle Scholar
  102. 102.
    Froghi S, Ahmed K, Khan MS, Dasgupta P, Challacombe B. Evaluation of robotic and laparoscopic partial nephrectomy for small renal tumours (T1a). BJU Int. 2013;112(4):E322–33.PubMedCrossRefGoogle Scholar
  103. 103.
    Bhan SN, Pautler SE, Shayegan B, Voss MD, Goeree RA, You JJ. Active surveillance, radiofrequency ablation, or cryoablation for the nonsurgical management of a small renal mass: a cost-utility analysis. Ann Surg Oncol. 2013;20(11):3675–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2016

Authors and Affiliations

  • Miltiadis E. Krokidis
    • 1
  • Franco Orsi
    • 2
  • Konstantinos Katsanos
    • 3
  • Thomas Helmberger
    • 4
  • Andy Adam
    • 3
  1. 1.Department of RadiologyCambridge University Hospitals NHS Foundation TrustCambridgeUK
  2. 2.Unit of Interventional RadiologyEuropean Institute of OncologyMilanItaly
  3. 3.Department of RadiologyGuy’s and St Thomas’ NHS Foundation TrustLondonUK
  4. 4.Department of Diagnostic and Interventional Radiology, Neuroradiology and Nuclear MedicineKlinikum MunichMunichGermany

Personalised recommendations